share_log

Stock Traders Buy Large Volume of Call Options on Sanofi (NASDAQ:SNY)

Defense World ·  Sep 24, 2022 01:21

Sanofi (NASDAQ:SNY – Get Rating) was the target of some unusual options trading activity on Friday. Traders bought 3,211 call options on the stock. This represents an increase of approximately 93% compared to the typical volume of 1,666 call options.

Sanofi Stock Down 1.9 %

SNY stock opened at $38.40 on Friday. The firm's fifty day simple moving average is $43.59 and its 200-day simple moving average is $48.58. The company has a market capitalization of $97.34 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. Sanofi has a 12 month low of $38.01 and a 12 month high of $58.10.

Get Sanofi alerts:

Sanofi (NASDAQ:SNY – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.85 by $0.07. Sanofi had a net margin of 16.60% and a return on equity of 25.99%. The business had revenue of $10.78 billion for the quarter, compared to the consensus estimate of $10.32 billion. As a group, equities research analysts forecast that Sanofi will post 4.14 earnings per share for the current year.

Institutional Trading of Sanofi

A number of hedge funds have recently added to or reduced their stakes in SNY. GHP Investment Advisors Inc. acquired a new position in Sanofi during the first quarter worth $26,000. Fairfield Bush & CO. acquired a new position in Sanofi during the first quarter worth $26,000. Eagle Bay Advisors LLC acquired a new position in Sanofi during the second quarter worth $28,000. Pinnacle Bancorp Inc. raised its position in Sanofi by 49.0% during the first quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company's stock worth $30,000 after acquiring an additional 193 shares during the period. Finally, Ahrens Investment Partners LLC acquired a new position in Sanofi during the first quarter worth $31,000. 10.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Sanofi from a "buy" rating to a "strong-buy" rating in a report on Sunday, August 14th. Morgan Stanley reduced their price objective on shares of Sanofi from €112.00 ($114.29) to €93.00 ($94.90) in a research note on Thursday, September 8th. UBS Group downgraded shares of Sanofi from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 9th. Cheuvreux downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Wednesday, August 24th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sanofi from €90.00 ($91.84) to €85.00 ($86.73) and set a "hold" rating on the stock in a research report on Wednesday, September 7th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $105.38.

About Sanofi

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Sanofi (SNY)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • 2 Semiconductor Stocks To Watch For Reversals

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment